BACKGROUNDCollaborative Development Agreement • November 14th, 2001 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • California
EX-10.12 9 d892618dex1012.htm COLLABORATIVE DEVELOPMENT AGREEMENT (GENETHON) * Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant...Collaborative Development Agreement • May 5th, 2020 • England and Wales
This COLLABORATIVE DEVELOPMENT AGREEMENT (the “Agreement”), effective as of January 24, 2014 (the “Effective Date”), is made by and between Audentes Therapeutics, Inc., a Delaware corporation, having a place of business at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104, USA (“Audentes”) and Genethon, a French not-for-profit organization organised under the French law of July 1, 1901, having a principal place of business at 1bis rue de l’Internationale, 91002 EVRY Cedex, France (“Genethon”).
1 EXHIBIT 10.14 [CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION] COLLABORATIVE DEVELOPMENT AGREEMENT THIS COLLABORATIVE DEVELOPMENT AGREEMENT dated as of...Collaborative Development Agreement • February 10th, 1997 • Biosite Diagnostics Inc • In vitro & in vivo diagnostic substances
COLLABORATIVE DEVELOPMENT AGREEMENT Between Health Enhancement Products Inc. and HEPI Pharmaceuticals, Inc.Collaborative Development Agreement • June 11th, 2007 • HEPI Pharmaceuticals, Inc. • Delaware
This Collaborative Development Agreement, effective as of the “Effective Date” (defined below), confirms the mutual understanding between Health Enhancement Products Inc., a Nevada corporation (“HEPI”), and HEPI Pharmaceuticals, Inc., a Delaware corporation (“HEPIPHARM”), each having a place of business at 7740 E. Evans Road, Suite A101, Scottsdale, AZ 85260. In this Agreement, HEPI and HEPIPHARM may also be referred to individually as “Party” and collectively as “Parties”.
ContractCollaborative Development Agreement • May 5th, 2020
EX-10.27 5 ex_1027xmicron.htm EXHIBIT COLLABORATIVE DEVELOPMENT AGREEMENT THIS COLLABORATIVE DEVELOPMENT AGREEMENT (“Agreement”) is entered into and effective as of the 1st day of April, 2013 (the “Effective Date”), by and between Micron Technology, Inc., a Delaware corporation with offices located at 8000 S. Federal Way, Boise, Idaho 83716 (“Micron”) and Intermolecular, Inc., a Delaware corporation with offices located at 3011 North First Street, San Jose, California 95134 (“Intermolecular”). WHEREAS Intermolecular and Elpida Memory, Inc., a Japanese corporation with offices located at 2-1, Yaesu 2-chome, Chuo-ku, Tokyo 104-0028, Japan (“Elpida”), have entered into certain agreements: Advanced Memory Development Program Agreement, dated May 22, 2008 (“Original Agreement”); Exhibit C - Royalty Terms, dated August 18, 2008 (“Amended Exhibit C”); Supplemental Joint Development Agreement, dated January 27, 2009 (“Supplemental Agreement”); Amendment to the Supplemental Joint Development Ag
The Institute of Medical Science, the University of Tokyo and Astellas Enter into a New Collaborative Development Agreement for Rice-Based Oral VaccineCollaborative Development Agreement • June 22nd, 2016
Tokyo, June 23, 2016 - the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori Murakami, “IMSUT”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that they have signed a new collaborative development agreement on the rice-based oral vaccine “MucoRice-CTB” (“MucoRice”) against cholera*1 and enterotoxigenic Escherichia coli (E coli) *2 caused diarrheal diseases.
COLLABORATIVE DEVELOPMENT AGREEMENTCollaborative Development Agreement • July 30th, 2003 • Pharmanetics Inc • Electromedical & electrotherapeutic apparatus • Delaware
This Agreement is made and entered into this 30th day of August, 2000 by and between PHARMANETICS, INC., a North Carolina corporation (“PharmaNetics”), and AVENTIS PHARMACEUTICALS PRODUCTS INC., a Delaware corporation (“Aventis”). PharmaNetics and Aventis are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
COLLABORATIVE DEVELOPMENT AGREEMENTCollaborative Development Agreement • January 8th, 2018 • IsoRay, Inc. • Surgical & medical instruments & apparatus • Delaware
This Collaborative Development Agreement (the “Agreement”), effective as of March 13, 2017, (the “Effective Date”), is made by and between IsoRay Medical, Inc., a Delaware corporation with offices at 350 Hills St., Suite 106, Richland, WA 99354 (“IsoRay”), and GammaTile, LLC, an Arizona limited liability company, having its principal place of business at 2242 E. Catclaw St Gilbert, AZ 85296 (“GammaTile LLC”). IsoRay and GammaTile LLC may be referred to herein individually as a “Party”, and collectively as the “Parties”.
COLLABORATIVE DEVELOPMENT AGREEMENTCollaborative Development Agreement • November 28th, 2017
WHEREAS AES Life Sciences is a company which is dedicated to providing the life science industry the most reliable, highest performance, and highest throughput whole column imaging detection capillary electrophoresis system for protein separation, quantification, and characterization,
PROTEIN SCIENCES CORPORATION AND VIREXX MEDICAL CORP. COLLABORATIVE DEVELOPMENT AGREEMENTCollaborative Development Agreement • November 28th, 2005 • Virexx Medical Corp • Biological products, (no disgnostic substances) • New York
THIS AGREEMENT is made by and between PROTEIN SCIENCES CORPORATION, 1000 Research Parkway, Meriden, CT 06450-7159 (“PSC”) and VIREXX MEDICAL CORP. 8223 Roper Road, Edmonton, Alberta, Canada T6E 6S4 (“VIREXX”) and is effective as of April 20, 2005 (“Effective Date”).
ADDENDUM TO COLLABORATIVE DEVELOPMENT AGREEMENT SEIKAGAKU CORPORATION - IDEC PHARMACEUTICALS CORPORATIONCollaborative Development Agreement • May 13th, 2002 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances)
THIS ADDENDUM TO COLLABORATIVE DEVELOPMENT AGREEMENT (“ADDENDUM”) is made and effective as of the 22nd day of March, 2002(“EFFECTIVE DATE”), by and between Seikagaku Corporation organized under Japanese law and having its principal executive offices at 1-5, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo 103-0023, Japan (“SK CORPORATION”) and IDEC Pharmaceuticals Corporation, a company (originally organized under the laws of the State of California and now organized under the laws of the State of Delaware) and having its principal executive offices at 3030 Callan Road, San Diego, California 92121, USA (“IDEC”), with reference to the following facts:
COLLABORATIVE DEVELOPMENT AGREEMENTCollaborative Development Agreement • April 19th, 2023 • Delaware
This Collaborative Development Agreement (the “Agreement”), effective as of March 13, 2017, (the “Effective Date”), is made by and between IsoRay Medical, Inc., a Delaware corporation with offices at 350 Hills St., Suite 106, Richland, WA 99354 (“IsoRay”), and GammaTile, LLC, an Arizona limited liability company, having its principal place of business at 2242 E. Catclaw St Gilbert, AZ 85296 (“GammaTile LLC”). IsoRay and GammaTile LLC may be referred to herein individually as a “Party”, and collectively as the “Parties”.
ContractCollaborative Development Agreement • November 9th, 2021
AGREEMENTCollaborative Development Agreement • March 17th, 1997 • Orphan Medical Inc • Pharmaceutical preparations • Minnesota
